• GeoVax received a Nasdaq staff determination to delist its common stock for failing the $1 minimum bid price rule.
• Shares traded below $1 for 30 consecutive business days from July 16, 2026 through Aug. 26, 2026.
• Nasdaq ruled GeoVax ineligible for the usual 180-day cure period due to its 1-for-25 reverse split on Jan. 12, 2026.
• Trading is expected to be suspended at the open on Sept. 8, 2026 without a timely hearing request.
• A hearing request by Sept. 3, 2026 would stay the delisting process while the appeal is pending.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GeoVax Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-029184), on August 28, 2026, and is solely responsible for the information contained therein.